Dr Eva Buchmeier speaks to ecancer about an updated analyses from the ADRIATIC trial evaluating consolidation durvalumab in patients with limited-stage small cell lung cancer following chemoradiotherapy.

Durvalumab not only improved overall and progression-free survival but also delayed the need for subsequent treatment and extended time to further disease progression.

Most patients received chemotherapy as their next line of therapy, while the use of immunotherapy after progression remained relatively low.

Importantly, the survival benefit with durvalumab remained consistent even after adjusting for the impact of subsequent treatments.

These findings reinforce the role of consolidation immunotherapy as a standard of care in this setting.